The blistering diseases.
The intent and purpose of the authors is to familiarize the reader with the principles that govern the diagnosis and management of autoimmune mucocutaneous blistering diseases. The purpose was not to be all-inclusive but illustrative. There are several other blistering diseases that have not been discussed because of the limited scope of this article. Of these, toxic epidermal necrolysis, erythema multiforme, and the like warrant the same attention and early recognition. These are covered in different articles. For the same reasons, certain genetically linked blistering diseases have not been discussed.
Scott
J E
JE
Department of Medicine, New England Baptist Hospital, Boston, Massachusetts, USA.
Ahmed
A R
AR
D001327:Autoimmune Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D002648:Child; D003874:Dermatitis Herpetiformis / Q000175:diagnosis / Q000188:drug therapy; D003937:Diagnosis, Differential; D016107:Epidermolysis Bullosa Acquisita / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy; D006559:Pemphigoid Gestationis / Q000175:diagnosis / Q000188:drug therapy; D010390:Pemphigoid, Benign Mucous Membrane / Q000175:diagnosis / Q000188:drug therapy; D010391:Pemphigoid, Bullous / Q000175:diagnosis / Q000188:drug therapy; D010392:Pemphigus / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy; D011247:Pregnancy; D011379:Prognosis; D012872:Skin Diseases, Vesiculobullous / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology
D007070:Immunoglobulin A